OPG and sRANKL serum levels and incident hip fracture in postmenopausal Caucasian women in the Women's Health Initiative Observational Study

Bone

Volumn 56, Issue 2, 2013, Pages 474-481

  LaCroix, Andrea Z ^a   Jackson, Rebecca D ^b   Aragaki, Aaron ^a   Kooperberg, Charles ^a   Cauley, Jane A ^c   Chen, Zhao ^d   LeBoff, Meryl S ^e   Duggan, David ^f   Wactawski Wende, Jean ^g  

^a Fred Hutchinson Cancer Research Center   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e HARVARD UNIVERSITY   (United States)

^f TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^g UNIVERSITY AT BUFFALO   (United States)

Author keywords

Hip fracture; Osteoporosis; Osteoprotogerin; Postmenopausal women; RANKL

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CALCIUM INTAKE; CASE CONTROL STUDY; CAUCASIAN; CONTROLLED STUDY; FEMALE; FRAX SCORE; HEALTH STATUS; HIP FRACTURE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; PHYSICAL ACTIVITY; PHYSICAL CAPACITY; POSTMENOPAUSE OSTEOPOROSIS; SCORING SYSTEM;

HIP FRACTURE; OPG; OSTEOPOROSIS; OSTEOPROTOGERIN; POSTMENOPAUSAL WOMEN; RANK; RANKL; RECEPTOR ACTIVATOR OF NF-KAPPA Β; RECEPTOR ACTIVATOR OF NF-KAPPA Β LIGAND; SOLUBLE RECEPTOR ACTIVATOR OF NF-KAPPA Β LIGAND; SRANKL; WHI; WOMEN'S HEALTH INITIATIVE;

AGED; CASE-CONTROL STUDIES; FEMALE; HIP FRACTURES; HUMANS; MIDDLE AGED; OSTEOPROTEGERIN; POSTMENOPAUSE; RANK LIGAND;

EID: 84882619099     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.05.018     Document Type: Article

References (28)

1. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001, 142:5050-5055.
2. Khosla S., Arrighi H.M., Melton L.J., Atkinson E.J., O'Fallon W.M., Dunstan C., et al. Correlates of osteoprotegerin levels in women and men. Osteoporos Int 2002, 13:394-399.
3. Stern A., Laughlin G.A., Bergstrom J., Barrett-Connor E. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study. Eur J Endocrinol 2007, 156:555-562.
4. Wagner D., Fahrleitner-Pammer A. Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: are they of any help?. Wien Med Wochenschr 2010, 160:452-457.
5. Browner W.S., Lui L.Y., Cummings S.R. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001, 86:631-637.
6. Jorgensen H.L., Kusk P., Madsen B., Fenger M., Lauritzen J.B. Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios. J Bone Miner Metab 2004, 22:132-138.
7. Jorgensen L., Hansen J.B., Brox J., Mathiesen E., Vik A., Jacobsen B.K. Serum osteoprotegerin levels are related to height loss: the Tromso Study. Eur J Epidemiol 2011, 26:305-312.
8. Schett G., Kiechl S., Redlich K., Oberhollenzer F., Weger S., Egger G., et al. Soluble RANKL and risk of nontraumatic fracture. JAMA 2004, 291:1108-1113.
9. Jorgensen L., Hansen J.B., Ahmen L., Bjornerem A., Emaus N., Joakimsen R., et al. Osteoprotegerin is associated with hip fracture incidence: the Tromso Study. Int J Epidemiol 2012, 41:1033-1039.
10. Hays J., Ockene J.K., Brunner R.L., Kotchen J.M., Manson J.E., Patterson R.E., et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2002, 348:1839-1854.
11. Curb J.D., McTiernan A., Heckbert S.R., Kooperberg C., Stanford J., Nevitt M., et al. WHI Morbidity and Mortality Committee, outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol 2003, 13:S122-S128.
12. Manson J.E., Greenland P., LaCroix A.Z., Stefanick M.L., Mouton C.P., Oberman A., et al. Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med 2002, 347:716-725.
13. Hays R.D., Sherbourne C.D., Mazel R.N. The RAND 36-Item Health Survey 1.0. Health Econ 1993, 2:217-227.
14. Patterson R.E., Kristal A.R., Tinker L.F., Carter T.A., Bolton M.P., Agurs-Collins T. Measurement characteristics of the Women's Health Initiative food frequency questionnaire. Ann Epidemiol 1999, 9:178-187.
15. Kanis J.A., Oden A., Johnell O., Johansson H., De Laet C., Brown J., et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007, 18:1033-1046.
16. Barbour K.E., Boudreau R., Danielson M.E., Youk A.O., Wactawski-Wende J., Greep N.C., et al. Inflammatory markers and the risk of hip fracture: the Women's Health Initiative. J Bone Miner Res 2012, 27:1167-1176.
17. Wood S.N. Stable and efficient multiple smoothing parameter estimation for generalized additive models. J Am Stat Assoc 2004, 99:673-686.
18. Woods N.F., LaCroix A.Z., Gray S.L., Aragaki A., Cochrane B.B., Brunner R.L., et al. Frailty: emergence and consequences in women aged 65 and older in the Women's Health Initiative Observational Study. J Am Geriatr Soc 2005, 53:1321-1330.
19. Abrahamsen B., Hjelmborg J.V., Kostenuik P., Stilgren L.S., Kyvik K., Adamu S., et al. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins. Bone 2005, 36:727-735.
20. Indridason O.S., Franzson L., Sigurdsson G. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporos Int 2005, 16:417-423.
21. Liu J.M., Zhao H.Y., Ning G., Zhao Y.J., Chen Y., Zhang Z., et al. Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75. Calcif Tissue Int 2005, 76:1-6.
22. Oh K.W., Rhee E.J., Lee W.Y., Kim S.W., Oh E.S., Baek K.H., et al. The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women. Clin Endocrinol (Oxf) 2004, 61:244-249.
23. Uemura H., Yasui T., Miyatani Y., Yamada M., Hiyoshi M., Arisawa K., et al. Circulating profiles of osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand in post-menopausal women. J Endocrinol Invest 2008, 31:163-168.
24. Jorgensen L., Vik A., Emaus N., Brox J., Hansen J.B., Mathiesen E., et al. Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromso Study. Osteoporos Int 2010, 21:931-938.
25. D'Amelio P., Roato I., D'Amico L., Veneziano L., Suman E., Sassi F., et al. Bone and bone marrow pro-osteoclastogenic cytokines are up-regulated in osteoporosis fragility fractures. Osteoporos Int 2011, 22:2869-2877.
26. Hofbauer L.C., Hicok K.C., Chen D., Khosla S. Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. Eur J Endocrinol 2002, 147:269-273.
27. Han K.O., Choi J.T., Choi H.A., Moon I.G., Yim C.H., Park W.K., et al. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone. Clin Endocrinol (Oxf) 2005, 62:349-353.
28. Kim J.G., Kim J.H., Lee D.O., Kim H., Kim J.Y., Suh C.S., et al. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women. Menopause 2008, 15:357-362.